StockData
Kura Oncology, Inc. logo

Kura Oncology, Inc. (KURA) shareholders

KURANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$7.34−0.15 (-2.00%)

Close on Nov 18, 2026Market cap $652.97MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
98.0%
87M of 89M shares
Institutional holders
220
28 new, 25 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
6 buys · 43 sales
Net bought $1.35M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Bvf Inc/Il
Joint filing with Bvf Partners L P/Il (9.99%), Lampert Mark N (9.99%) and 3 more
8,677,0189.99%13G (passive) amendmentSep 30, 2025
Aaron Cowen
Joint filing with Montanova Capital, LLC (9.70%), Averill Master Fund, Ltd. (8.80%)
8,575,4229.70%13G (passive) amendmentJun 30, 2026
BlackRock, Inc.7,908,8328.90%13G (passive) amendmentSep 30, 2026
Suvretta Capital Management, LLC
Joint filing with Aaron Cowen (6.70%), Averill Master Fund, Ltd. (5.90%)
5,198,1896.70%13G (passive) amendmentDec 31, 2024
Armistice Capital, LLC
Joint filing with Steven Boyd (5.67%)
4,936,0005.67%13G (passive) amendmentDec 31, 2025
State Street Corporation4,931,0905.70%13G (passive)Dec 31, 2025
Vanguard Capital Management4,428,8125.01%13G (passive)Mar 31, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of KURAValueChange% of portfolio
BlackRock, Inc.10,509,23311.81%$115.29M+871,7020.00%
Suvretta Capital Management, LLC8,575,4229.64%$94.07M–1.72%
Bvf Inc/Il8,445,7699.49%$92.65M–2.37%
State Street Corp5,329,2085.99%$58.46M+817,3170.00%
Vanguard Capital Management LLC3,916,1644.40%$42.96M+130,4790.00%
Armistice Capital, LLC3,678,0004.13%$40.35M−58,0000.49%
Aqr Capital Management LLC3,126,7273.51%$34.30M+1,002,2470.01%
Goldman Sachs Group Inc2,265,1712.55%$24.85M+831,7000.00%
Geode Capital Management, LLC2,229,9582.51%$24.47M+195,6820.00%
Alethea Capital Management, LLC2,167,9382.44%$23.78M+638,5699.85%
Prosight Management, LP2,021,9642.27%$22.18M−1,334,7363.82%
Deep Track Capital, LP1,978,5652.22%$21.70M−664,9770.32%
Renaissance Technologies LLC1,663,7651.87%$18.25M+81,1970.03%
Arrowstreet Capital, Limited Partnership1,410,2751.59%$15.47MNew0.01%
Vanguard Portfolio Management LLC1,329,9411.49%$14.59M+99,1390.00%
Nan Fung Trinity (Hk) Ltd1,174,8801.32%$12.89M+110,0001.27%
Qube Research & Technologies Ltd1,169,8841.32%$12.83M−466,8490.01%
Dimensional Fund Advisors LP1,169,1891.31%$12.83M−256,7560.00%
Bank Of America Corp /De/1,160,9211.30%$12.74M−69,2100.00%
Morgan Stanley1,160,3101.30%$12.73M−3,6670.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202622087M98.0%28 / 9264 / 2512M9M
Q1 202622284M94.9%37 / 6983 / 2715M11M
Q4 202521585M96.0%44 / 9055 / 2712M10M
Q3 202520084M94.3%43 / 7651 / 2414M12M
Q2 202518282M92.3%29 / 8345 / 2913M12M
Q1 202518380M90.4%36 / 6256 / 3615M13M
Q4 202418579M88.6%48 / 7036 / 4124M28M
Q3 202417983M93.1%22 / 6353 / 1614M6M
Q2 202417481M90.9%29 / 5561 / 196M9M
Q1 202416584M94.3%40 / 5547 / 1512M9M
Q4 202314081M90.6%22 / 4943 / 1510M5M
Q3 202313375M84.7%9 / 6434 / 246M5M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

172 funds held KURA in Q2 2026, 68% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of KURAValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF3,105,7473.49%$34.07M0.32%Jun 30, 2026
Vanguard Total Stock Market Index Fund2,799,3383.15%$30.71M0.00%Jun 30, 2026
iShares Russell 2000 ETF2,210,6142.48%$24.25M0.03%Jun 30, 2026
Vanguard Extended Market Index Fund1,026,9431.15%$11.27M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund928,9881.04%$8.37M0.02%Jul 31, 2026
iShares Russell 2000 Growth ETF785,0960.88%$8.61M0.06%Jun 30, 2026
iShares Biotechnology ETF606,1130.68%$6.65M0.07%Jun 30, 2026
BlackRock Advantage Small Cap Core Fund564,9790.64%$5.76M0.11%May 29, 2026
Fidelity Extended Market Index Fund451,5470.51%$4.61M0.01%May 31, 2026
Vanguard Russell 2000 Index Fund414,4580.47%$4.23M0.02%May 31, 2026
Schwab U.S. Small-Cap ETF413,8200.47%$4.22M0.02%May 31, 2026
Vanguard Strategic Small-Cap Equity Fund300,3210.34%$3.29M0.11%Jun 30, 2026
U.S. Small Cap Portfolio268,9200.30%$2.42M0.01%Jul 31, 2026
Fidelity Enhanced Small Cap Core ETF263,8390.30%$2.89M0.05%Jun 30, 2026
Vanguard Explorer Fund245,0510.28%$2.21M0.01%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Troy Edward WilsonPresident and CEO, Director1,414,6501.59%Nov 17, 2026
Thomas James DoyleSVP, Finance & Accounting138,5810.16%Nov 18, 2026
Kathleen FordChief Operating Officer132,2760.15%Nov 18, 2026
Brian T. PowlChief Commercial Officer113,2650.13%Nov 18, 2026
Teresa Brophy BairChief Legal Officer178,4010.20%Nov 18, 2026
Mollie LeoniChief Medical Officer99,8450.11%Nov 18, 2026
Francis BurrowsChief Scientific Officer63,0530.07%Sep 25, 2026
Jennifer FulkChief Financial Officer––Sep 10, 2026
Helen Louise CollinsDirector––Jun 4, 2026
Diane L. ParksDirector––Jun 4, 2026
Faheem HasnainDirector23,9830.03%Jun 4, 2026
Mary T. SzelaDirector––Jun 4, 2026
Thomas MalleyDirector149,5570.17%Jun 4, 2026
Michael VasconcellesDirector––Jun 4, 2026
Carol SchaferDirector––Jun 4, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Mollie Leoni
Chief Medical Officer
Nov 17, 2026Sale(10b5-1 plan)−22,241$7.45$165.70K99,845
Brian T. Powl
Chief Commercial Officer
Nov 17, 2026Sale(10b5-1 plan)−15,254$7.45$113.64K113,265
Kathleen Ford
Chief Operating Officer
Nov 17, 2026Sale(10b5-1 plan)−3,668$7.46$27.36K132,276
Thomas James Doyle
SVP, Finance & Accounting
Nov 16, 2026Sale−4,697$7.44$34.95K138,081
Mollie Leoni
Chief Medical Officer
Nov 16, 2026Sale(10b5-1 plan)−19,009$7.44$141.43K122,086
Brian T. Powl
Chief Commercial Officer
Nov 16, 2026Sale(10b5-1 plan)−9,196$7.44$68.42K127,623
Teresa Brophy Bair
Chief Legal Officer
Nov 16, 2026Sale(10b5-1 plan)−8,601$7.44$63.99K178,401
Kathleen Ford
Chief Operating Officer
Nov 16, 2026Sale(10b5-1 plan)−7,042$7.44$52.39K135,944
Troy Edward Wilson
President and CEO, Director
Nov 16, 2026Buy+101,119$7.42$750.30K679,194
Troy Edward Wilson
President and CEO, Director
Nov 16, 2026Buy+101,119$7.42$750.30K635,456
Troy Edward Wilson
President and CEO, Director
Nov 13, 2026Buy+98,881$7.63$754.46K578,075
Troy Edward Wilson
President and CEO, Director
Nov 13, 2026Buy+98,881$7.63$754.46K534,337
Brian T. Powl
Chief Commercial Officer
Sep 29, 2026Sale(10b5-1 plan)−15,430$10.75$165.87K136,819
Kathleen Ford
Chief Operating Officer
Sep 29, 2026Sale(10b5-1 plan)−3,668$10.75$39.43K142,986
Mollie Leoni
Chief Medical Officer
Sep 29, 2026Sale(10b5-1 plan)−28,802$10.75$309.62K141,095
Teresa Brophy Bair
Chief Legal Officer
Sep 28, 2026Sale(10b5-1 plan)−8,442$10.50$88.64K187,002
Brian T. Powl
Chief Commercial Officer
Sep 28, 2026Sale(10b5-1 plan)−8,000$10.56$84.48K152,249
Brian T. Powl
Chief Commercial Officer
Sep 28, 2026Sale(10b5-1 plan)−9,020$10.50$94.71K160,249
Kathleen Ford
Chief Operating Officer
Sep 28, 2026Sale(10b5-1 plan)−6,906$10.50$72.51K146,654
Thomas James Doyle
SVP, Finance & Accounting
Sep 28, 2026Sale−4,607$10.50$48.37K142,428
Mollie Leoni
Chief Medical Officer
Sep 28, 2026Sale(10b5-1 plan)−12,448$10.50$130.70K169,897
Francis Burrows
Chief Scientific Officer
Sep 24, 2026Option exercise+30,000$6.15$184.50K63,053
Francis Burrows
Chief Scientific Officer
Sep 24, 2026Sale−20,726$10.83$224.46K42,327
Troy Edward Wilson
President and CEO, Director
Aug 24, 2026Buy+100,000$12.39$1.24M479,194
Brian T. Powl
Chief Commercial Officer
Aug 21, 2026Sale(10b5-1 plan)−4,345$11.89$51.66K169,269
Teresa Brophy Bair
Chief Legal Officer
Aug 19, 2026Sale(10b5-1 plan)−31,487$12.63$397.68K195,444
Troy Edward Wilson
President and CEO, Director
Aug 17, 2026Buy+100,000$11.12$1.11M379,194
Mollie Leoni
Chief Medical Officer
Jun 18, 2026Sale(10b5-1 plan)−84,929$9.82$834.00K182,345
Brian T. Powl
Chief Commercial Officer
May 21, 2026Sale(10b5-1 plan)−10,000$11.00$110.00K173,614
Brian T. Powl
Chief Commercial Officer
May 19, 2026Sale(10b5-1 plan)−339$9.21$3.12K183,614
Kathleen Ford
Chief Operating Officer
May 19, 2026Sale(10b5-1 plan)−2,257$9.08$20.49K153,560
Teresa Brophy Bair
Chief Legal Officer
May 18, 2026Sale(10b5-1 plan)−2,256$9.38$21.16K226,931
Troy Edward Wilson
President and CEO, Director
Mar 23, 2026Option exercise+6,103$6.15$37.53K435,456
Thomas Malley
Director
Mar 18, 2026Option exercise+10,000$3.12$31.20K10,000
Francis Burrows
Chief Scientific Officer
Jan 27, 2026Sale−1,311$8.46$11.09K32,424
Kathleen Ford
Chief Operating Officer
Jan 27, 2026Sale−1,813$8.46$15.34K153,560
Mollie Leoni
Chief Medical Officer
Jan 27, 2026Sale−2,233$8.46$18.89K269,566
Mollie Leoni
Chief Medical Officer
Jan 27, 2026Sale−3,655$8.46$30.92K271,799
Mollie Leoni
Chief Medical Officer
Jan 27, 2026Sale−951$8.46$8.05K268,615
Mollie Leoni
Chief Medical Officer
Jan 27, 2026Sale−1,341$8.46$11.34K267,274
Teresa Brophy Bair
Chief Legal Officer
Jan 27, 2026Sale−4,096$8.46$34.65K234,043
Teresa Brophy Bair
Chief Legal Officer
Jan 27, 2026Sale−2,335$8.46$19.75K231,708
Teresa Brophy Bair
Chief Legal Officer
Jan 27, 2026Sale−4,777$8.46$40.41K226,931
Brian T. Powl
Chief Commercial Officer
Jan 27, 2026Sale−4,842$8.46$40.96K184,847
Brian T. Powl
Chief Commercial Officer
Jan 27, 2026Sale−1,572$8.46$13.30K183,275
Thomas James Doyle
SVP, Finance & Accounting
Jan 27, 2026Sale−2,226$8.46$18.83K150,083
Thomas James Doyle
SVP, Finance & Accounting
Jan 27, 2026Sale−881$8.46$7.45K145,167
Thomas James Doyle
SVP, Finance & Accounting
Jan 27, 2026Sale−2,226$8.46$18.83K146,048
Thomas James Doyle
SVP, Finance & Accounting
Jan 27, 2026Sale−695$8.46$5.88K148,274
Thomas James Doyle
SVP, Finance & Accounting
Jan 27, 2026Sale−1,114$8.46$9.42K148,969
Teresa Brophy Bair
Chief Legal Officer
Jan 2, 2026Award+50,000––238,139
Thomas James Doyle
SVP, Finance & Accounting
Jan 2, 2026Award+21,250––152,309
Mollie Leoni
Chief Medical Officer
Jan 2, 2026Award+50,000––275,454
Kathleen Ford
Chief Operating Officer
Jan 2, 2026Award+50,000––155,373
Brian T. Powl
Chief Commercial Officer
Jan 2, 2026Award+50,000––189,689
Francis Burrows
Chief Scientific Officer
Dec 18, 2025Option exercise+35,000$4.80$168.00K57,461
Francis Burrows
Chief Scientific Officer
Dec 18, 2025Sale−23,726$9.78$232.04K33,735
Faheem Hasnain
Director
Dec 9, 2025Sale(10b5-1 plan)−10,000$10.98$109.80K23,983
Faheem Hasnain
Director
Dec 9, 2025Option exercise+10,000$3.12$31.20K33,983
Mollie Leoni
Chief Medical Officer
Nov 14, 2025Sale−15,485$11.18$173.12K225,454

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
14.60%
13M shares short
Days to cover
7.9
At 2M shares a day
Change since last report
-11.7%
From 14M shares
Short volume, 20 days
55.0%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Kura Oncology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,963 shares on Sep 17, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Mollie Leoni
Officer
Sep 29, 202628,802$305.59KSep 29, 2026Performance Stock Units
Brian T. Powl
Officer
Sep 29, 202615,430$163.71KSep 29, 2026Restricted Stock Units
Kathleen Ford
Officer
Sep 29, 20263,668$38.92KSep 29, 2026Performance Stock Units
Kathleen Ford
Officer
Sep 28, 20266,906$74.31KSep 28, 2026PSU
Brian T. Powl
Officer
Sep 28, 20269,020$97.06KSep 28, 2026RSU
Brian T. Powl
Officer
Sep 28, 20268,000$86.08KSep 28, 2026Restricted Stock Units
Thomas James Doyle
Officer
Sep 28, 20264,607$49.57KSep 28, 2026PSU
Teresa Brophy Bair
Officer
Sep 28, 20268,442$90.84KSep 28, 2026PSU
Mollie Leoni
Officer
Sep 28, 202612,448$133.94KSep 28, 2026PSU
Francis Burrows
Officer
Sep 24, 202620,726$224.51KSep 24, 2026Stock Option Exercise
Brian T. Powl
Officer
Aug 21, 20264,345$50.88KAug 21, 2026Restricted Stock Units
Teresa Brophy Bair
Officer
Aug 19, 202631,487$388.23KAug 19, 2026Restricted Stock Units
Mollie Leoni
Officer
Jun 18, 202684,929$812.77KJun 18, 2026Restricted Stock Units
Brian T. Powl
Officer
May 21, 202610,000$103.40KMay 21, 2026Restricted Stock Units
Brian T. Powl
Officer
May 19, 2026339$3.12KMay 19, 2026Employee Stock Purchase Plan

Congress trades

1 trade in Kura Oncology reported by 1 member of the House

MemberTypeTradedAmountFiled
Christopher L. Jacobs
NY27
BoughtDec 12, 2022$1K–15KJan 20, 2023

See a number that looks wrong?